Interleukin board member to resign

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Essential IR Insights Newsletter - Summer July-August 2023

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits

Roger Colman is resigning from the Interleukin Genetics Inc. board on Dec. 30.

He was nominated by Pyxis Innovations Inc. following an investment in Interleukin Genetics. Colman is also retiring from Pyxis.

Pyxis Innovations can appoint two directors to the Interleukin Genetics board but is waiving off its right to name a replacement for Colman.

Joseph Landstra continues to represent Pyxis on the Interleukin board.